# GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

> **NCT01813422** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 970 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01813422
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-18
- **Primary completion:** 2016-07-12
- **Final completion:** 2016-07-29
- **Target enrollment:** 970 (ACTUAL)
- **Last updated:** 2019-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813422, "GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01813422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*